Abstract
Clinical trials have shown that giving anti-oestrogens to healthy women can reduce the early incidence of breast cancer by approximately 40%. However, the large numbers of women treated, compared with the few who get breast cancer, together with the not insignificant toxicity and the unknown long-term clinical benefits and risks, makes this strategy of prevention versus treatment precarious. So how can we improve the odds for the successful use of endocrine chemoprevention?
MeSH terms
-
Antineoplastic Agents, Hormonal / therapeutic use*
-
Breast Neoplasms / prevention & control*
-
Clinical Trials as Topic
-
Estrogen Receptor Modulators / therapeutic use*
-
Estrogens / adverse effects
-
Estrogens / therapeutic use
-
Humans
-
Models, Anatomic
-
Models, Biological
-
Models, Chemical
-
Random Allocation
-
Receptors, Estrogen / metabolism
-
Risk Factors
-
Tamoxifen / adverse effects
-
Tamoxifen / therapeutic use
Substances
-
Antineoplastic Agents, Hormonal
-
Estrogen Receptor Modulators
-
Estrogens
-
Receptors, Estrogen
-
Tamoxifen